Pharmacodynamic aspects of two sulphonylurea derivatives glipizide and glibenclamide.
D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003510:Cyclohexanes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004285:Dogs; D005947:Glucose / Q000008:administration & dosage; D005905:Glyburide / Q000494:pharmacology*; D006943:Hyperglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007328:Insulin / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D010179:Pancreas / Q000187:drug effects; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D011719:Pyrazines; D013453:Sulfonylurea Compounds; D005947:Glucose; D005905:Glyburide